Verastem Inc (VSTM)

May 12, 2026, 7:30 AM EDT - 1 day ago

Verastem Oncology to Present at Upcoming Investor Conferences

2026-05-08T12:55:59.000Z - 4 days ago

Verastem price target lowered to $18 from $19 at BTIG

May 8, 2026, 7:30 AM EDT - 5 days ago

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

2026-05-08T11:20:06.000Z - 5 days ago

Verastem price target raised to $18 from $16 at Alliance Global

2026-05-07T21:47:04.000Z - 5 days ago

Verastem reports Q1 adjusted EPS (43c), consensus (47c)

May 7, 2026, 4:30 PM EDT - 5 days ago

Verastem Earnings Call Transcript: Q1 2026

May 7, 2026, 4:01 PM EDT - 5 days ago

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

2026-04-30T11:53:49.000Z - 13 days ago

Verastem announces launch of Reimagine Recurrent LGSOC campaign

Apr 30, 2026, 7:30 AM EDT - 13 days ago

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Apr 23, 2026, 7:30 AM EDT - 20 days ago

Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026

2026-04-10T11:05:38.000Z - 4 weeks ago

Verastem announces two-year median follow-up data on AVMAPKI FAKZYNJA combo

Apr 10, 2026, 7:00 AM EDT - 4 weeks ago

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers

Apr 2, 2026, 4:05 PM EDT - 5 weeks ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-03-30T13:00:48.000Z - 6 weeks ago

Verastem assumed with a Buy at Jefferies

2026-03-26T21:06:04.000Z - 6 weeks ago

Verastem management to meet with Cantor

Mar 17, 2026, 6:03 PM EDT - 2 months ago

Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026

Mar 17, 2026, 4:44 PM EDT - 2 months ago

Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers

2026-03-11T20:28:30.000Z - 2 months ago

Verastem assumed with a Buy at BTIG

2026-03-05T12:09:05.000Z - 2 months ago

Verastem price target raised to $18 from $16 at Alliance Global

Mar 4, 2026, 4:30 PM EST - 2 months ago

Verastem Earnings Call Transcript: Q4 2025

2026-03-04T21:06:51.000Z - 2 months ago

Verastem reports Q4 adjusted EPS (48c), consensus (50c)

2026-03-04T21:06:00.000Z - 2 months ago

Verastem announces upcoming key milestones

Mar 4, 2026, 4:01 PM EST - 2 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

2026-02-19T12:27:12.000Z - 2 months ago

Verastem price target raised to $18 from $15 at Mizuho

Feb 18, 2026, 7:30 AM EST - 2 months ago

Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Feb 11, 2026, 2:00 PM EST - 3 months ago

Verastem Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-02-04T13:00:39.000Z - 3 months ago

Verastem reports preliminary Q4 revenue $17.5M, consensus $16.53M

Feb 4, 2026, 7:30 AM EST - 3 months ago

Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

2026-02-04T11:10:47.000Z - 3 months ago

Verastem assumed with a Buy at H.C. Wainwright

2025-12-30T11:35:27.000Z - 4 months ago

Verastem ending RAMP 203 study doesn’t impact thesis, says Guggenheim

2025-12-29T21:05:32.000Z - 4 months ago

Verastem to discontinue RAMP 203 clinical trial

Dec 29, 2025, 4:01 PM EST - 4 months ago

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Dec 15, 2025, 4:01 PM EST - 5 months ago

Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

Dec 2, 2025, 10:25 AM EST - 5 months ago

Verastem Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 25, 2025, 7:30 AM EST - 6 months ago

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

Nov 19, 2025, 9:30 AM EST - 6 months ago

Verastem Transcript: Jefferies London Healthcare Conference 2025

Nov 14, 2025, 12:41 AM EST - 6 months ago

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 13, 2025, 4:07 PM EST - 6 months ago

Verastem Oncology Announces Proposed Public Offering of Common Stock

Nov 11, 2025, 1:00 PM EST - 6 months ago

Verastem Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 4, 2025, 8:00 AM EST - 6 months ago

Verastem Earnings Call Transcript: Q3 2025

Nov 4, 2025, 7:30 AM EST - 6 months ago

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Oct 23, 2025, 4:01 PM EDT - 7 months ago

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Oct 23, 2025, 7:30 AM EDT - 7 months ago

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Oct 19, 2025, 4:15 AM EDT - 7 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Sep 8, 2025, 12:00 PM EDT - 8 months ago

Verastem Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 3:55 PM EDT - 8 months ago

Verastem Transcript: Cantor Global Healthcare Conference 2025

Aug 13, 2025, 4:29 PM EDT - 9 months ago

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Verastem Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 9 months ago

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Jul 29, 2025, 7:30 AM EDT - 10 months ago

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 24, 2025, 7:30 AM EDT - 10 months ago

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Jul 11, 2025, 4:12 PM EDT - 10 months ago

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Jun 30, 2025, 4:02 PM EDT - 11 months ago

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Jun 24, 2025, 4:02 PM EDT - 11 months ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Jun 4, 2025, 4:20 PM EDT - 1 year ago

Verastem Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 12:00 PM EDT - 1 year ago

Verastem Transcript: R&D Day 2025

Jun 2, 2025, 9:40 AM EDT - 1 year ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

May 28, 2025, 7:30 AM EDT - 1 year ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 5:01 PM EDT - 1 year ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 20, 2025, 3:35 PM EDT - 1 year ago

Verastem Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 12:00 PM EDT - 1 year ago

Verastem Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 8:30 AM EDT - 1 year ago

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

TEM

May 13, 2025, 4:34 PM EDT - 1 year ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 8, 2025, 1:17 PM EDT - 1 year ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025, 12:23 PM EDT - 1 year ago

U.S. FDA approves Verastem's cancer therapy

Apr 25, 2025, 9:00 AM EDT - 1 year ago

Verastem Oncology Announces $75 million Private Placement

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Mar 25, 2025, 4:35 PM EDT - 1 year ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Feb 20, 2025, 4:05 PM EST - 1 year ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Feb 5, 2025, 1:00 PM EST - 1 year ago

Verastem Transcript: Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Jan 15, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Jan 14, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Jan 13, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Dec 30, 2024, 4:30 PM EST - 1 year ago

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Dec 18, 2024, 7:30 AM EST - 1 year ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Dec 3, 2024, 11:15 AM EST - 1 year ago

Verastem Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 13, 2024, 9:00 AM EST - 1 year ago

Verastem Transcript: Guggenheim Inaugural Global Healthcare Innovation Conference

Nov 6, 2024, 4:05 PM EST - 1 year ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer